N Health

Chronic Myeloid Leukemia

24 April 2018

BCR/ABL Quantitative RQ-PCR for Chronic Myeloid Leukemia Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder which can be found about 15% of adult Leukemia. In up to 95% of CML patients have Philadelphia chromosome, a balanced translocation of chromosome 9 and chromosome 22. This translocation causes a BCR/ABL fusion gene which creates a constitutively active tyrosine kinase leading to uncontrolled proliferation. The treatment of CML was revolutionized by the introduction of the first targeted therapy drug for CML, a BCR-ABL tyrosine kinase inhibitor (TKI). The drug targets to specific protein which is expressed by BCR/ABL fusion gene and The clinical use of specific BCR-ABL inhibitors has resulted in a significantly improved response rate, overall survival, prognosis and patient outcome in CML patients compared to previous therapeutic regimens. After drug initiation, BCR/ABL mRNA level of CML patient will continuously decrease and will be undetected by Quantitative Real-time PCR technique. However, there are some patients who do not response to the first generation TKI or relapse. The patient should monitor the BCR/ABL mRNA continuously to get the most suitable and effective therapy. N Health provides the testing for quantify the level of BCR/ABL mRNA by using quantitative RQ-PCR technique as in the table below. The test should be under the discretion of a physician.  |  The mentioned test is performed by the laboratory with ISO 15189 certification and lab accreditation. *This operation schedule is for the test performed at N Health head quarter, Bangkok. **Above turnaround time does not include logistic time. For BDMS network hospitals, please contact N Health laboratory located at your hospitals. References 1. NCCN guidelines for Chronic Myeloid Leukemia 2 Version 2.2017 2. https://tci-thaijo.org/index.php/tstj/article/view/85102 Download N Test BCR/ABL